Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00178620 · ClinicalTrials.gov registry record · Phase 4
Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization
A Phase 4 study of Myocardial Infarction and Heart Disease, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 4
- Development phase
- 390
- Enrollment target
- 1
- Study location
NCT00178620 is a Phase 4 study of Myocardial Infarction and Heart Disease that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 390 participants, below the 4,676-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00178620, a Phase 4 study of Myocardial Infarction and Heart Disease, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 390 participants
- Enrollment target
- 1
- Study location
Study Summary
The PATCAR study has been designed to test the hypothesis that the strategy of pre-hospital use of a "clot busting" (thrombolytic) drug followed with emergent heart catheterization including stenting of the problematic coronary artery, will result in a lower mortality and reduced repeat heart attack rates. Early identifying and treating heart attacks patients prior to the arriving at the hospital, in those patients who qualify for the "clot busting" drugs will lower the size of the heart attack damage. This smaller heart attack will lead to fewer problems with less repeat heart attacks and death in the future.
Conditions Studied
Interventions
- DRUG Reteplase 10 Units (U) plus a second dose of reteplase 10 U
- DRUG Reteplase 10 U
- PROCEDURE Urgent Percutaneous Coronary Intervention (PCI)
- PROCEDURE Primary Percutaneous Coronary Intervention (PCI)
Study Locations (1)
Texas
- Memorial Hermann Hospital / The University of Texas HSC - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 390 participants |
| Start Date | 2003-09 |
| Est. Completion | 2009-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00178620
The ClinicalTrials.gov registry entry for NCT00178620 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 390 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,676-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (92% lower). The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Myocardial Infarction appearing as the primary indexed condition, and to 4 interventions - of which Reteplase 10 Units (U) plus a second dose of reteplase 10 U is the first listed.
NCT00178620 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00178620 about?
NCT00178620 is a clinical study titled "Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization". The PATCAR study has been designed to test the hypothesis that the strategy of pre-hospital use of a "clot busting" (thrombolytic) drug followed with emergent heart catheterization including stenting of the problematic coronary artery, will result in a lower mortality and reduced repeat heart attack...
What is the current status of trial NCT00178620?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 390 participants. The study started on 2003-09. Estimated completion is 2009-12.
What conditions does trial NCT00178620 study?
This clinical trial studies the following conditions: Myocardial Infarction, Heart Disease, Acute Myocardial Infarction.
What interventions are being tested in trial NCT00178620?
The interventions under investigation include: Reteplase 10 Units (U) plus a second dose of reteplase 10 U (DRUG), Reteplase 10 U (DRUG), Urgent Percutaneous Coronary Intervention (PCI) (PROCEDURE), Primary Percutaneous Coronary Intervention (PCI) (PROCEDURE).
Who is sponsoring clinical trial NCT00178620?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00178620 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myocardial Infarction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
ACTIVE NOT RECRUITING · Phase 4
-
A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients
COMPLETED · Phase 4
-
Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease
COMPLETED · Phase 4
-
INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure
COMPLETED · Phase 4
-
Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence
RECRUITING
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.